Blocking the glycolytic activator PFKFB3 using the small molecule 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) decreased vessel leakiness, improved perfusion, and promoted vessel normalization in a melanoma mouse model [20], and reduced EC growth in vitro and in vivo in a pathological ocular angiogenesis model [24]. Here, PFKFB3 is linked to melanoma.